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A B S T R A C T
In HIV infected macrophages, a large population of viral genomes persists as the unintegrated form (uDNA) that
is transcriptionally active. However, how this transcriptional activity is controlled remains unclear. In this re-
port, we investigated whether Tat, the viral transactivator of transcription, is involved in uDNA transcription.
We demonstrate that de novo Tat activity is generated from uDNA, and this uDNA-derived Tat (uTat) transac-
tivates the uDNA LTR. In addition, uTat is required for the transcriptional persistence of uDNA that is assembled
into repressive episomal minichromatin. In the absence of uTat, uDNA minichromatin is gradually silenced, but
remains highly inducible by HDAC inhibitors (HDACi). Therefore, functionally, uTat antagonizes uDNA mini-
chromatin repression to maintain persistent viral transcription in macrophages. uTat-mediated viral persistence
may establish a viral reservoir in macrophages where uDNA were found to persist.
1. Introduction
The natural process of HIV infection leads to the accumulation of a
large amount of unintegrated viral DNA (uDNA) in CD4 T cells, mac-
rophages, lymphoid tissues, and the brain (Chun et al., 1997; Pang
et al., 1990; Pauza et al., 1990; Shaw et al., 1984; Teo et al., 1997). In
cell culture conditions, uDNA has been found to possess transcriptional
activity, which can generate all three classes of viral transcripts: the
multiply spliced, the singly spliced, and the non-spliced (Kelly et al.,
2008; Wu and Marsh, 2001, 2003). Nevertheless, only viral early pro-
teins such as Nef are selectively translated in primary T cells and
macrophages in the absence of cellular stimulation (Kelly et al., 2008;
Wu and Marsh, 2001, 2003). This selective transcription has been
suggested to be a normal early process of HIV infection of human T cells
and macrophages (Kelly et al., 2008; Wu, 2004; Wu and Marsh, 2001,
2003). In particular, in cultured macrophages, uDNA can persist for at
least 30 days and remain transcriptionally active at a low level (Gillim-
Ross et al., 2005a; Kelly et al., 2008).
Functionally, the production of Nef from uDNA has been suggested
to facilitate HIV-1 infection by lowering the threshold of T cell
activation (Fenard et al., 2005; Schrager and Marsh, 1999; Wu and
Marsh, 2001). This early Nef from uDNA can also effectively down-
modulate surface receptors such as CD4, CXCR4/CCR5, and MHC class I
(Gillim-Ross et al., 2005b; Sloan et al., 2011a, 2011b). In addition,
uDNA can stimulate the production of numerous inflammatory che-
mokines such as CXCL8 (IL-8), CXCL9, and CXCL10 (IP-10) in macro-
phages (Kelly et al., 2008). The persistence of uDNA in immune cells,
such as blood resting CD4 T cells and macrophages, has also been
suggested to serve as alternative form of viral reservoirs, which can be
readily reactivated by T cell activation, cytokines, gut-associated short
chain fatty acids, or other latency reversing agents for gene expression,
and even low level viral replication (Chan et al., 2016; Gelderblom
et al., 2008; Kantor et al., 2009; Petitjean et al., 2007; Trinite et al.,
2013; Wu, 2008). In addition, genetic complementation between un-
integrated and integrated viral genomes can occur, and this process has
been suggested to be essential to prevent possible losses of viral genetic
diversity (Gelderblom et al., 2008; Wu, 2008). Thus, the two tran-
scriptional processes, occurring before and after HIV integration, are
intimately linked to facilitate viral infection, latency, and persistence
(Wodarz et al., 2014; Wu, 2008).
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Recent studies have also suggested that preintegration transcription
occurs at a large scale, and the number of transcribing uDNA approx-
imates to those of proviral genomes (Iyer et al., 2009). However, each
uDNA template transcribes at a homogenously low level (Iyer et al.,
2009). This raises the question of whether this low level transcription is
regulated by Tat, the viral transactivator of transcription. Tat stimulates
viral gene expression by binding to the transactivation response (TAR)
element on RNA and recruits factors such as cyclin T1 and CDK9 (P-
TEFb) for transcriptional initiation and polymerase processivity
(Herrmann and Rice, 1993, 1995; Mancebo et al., 1997; Wei et al.,
1998; Zhu et al., 1997). Tat can also directly bind to components of the
ATP-dependent chromatin remodeling complex SWI-SNF (Agbottah
et al., 2006; Mahmoudi et al., 2006; Treand et al., 2006) and recruits
the complex to the HIV promoter (Agbottah et al., 2006; Mahmoudi
et al., 2006; Treand et al., 2006). In addition, Tat can bind to HAT
(histone acetyltransferase) such as p300/CBP, pCAF, and hGCN5
(Benkirane et al., 1998; Col et al., 2001; Hottiger and Nabel, 1998;
Kamine et al., 1996; Marzio et al., 1998), which may promote acet-
ylation of nucleosomes and Tat itself to enhance Tat-mediated trans-
activation (Gatignol, 2007; Kiernan et al., 1999). Nevertheless, given
the low transcriptional activity of uDNA, the role of Tat in activating
uDNA transcription remained uncertain. In this article, we examined
the role of Tat in regulating uDNA transcription and viral persistence in
primary macrophages.
2. Materials and methods
2.1. Approvals from IRB and IACUC
Peripheral blood was drawn from HIV-negative donors. All proto-
cols involving human subjects were reviewed and approved by the
George Mason University (GMU) IRB. Informed written consents from
the human subjects were obtained in this study.
2.2. Plasmids and DNA cloning
Plasmids HIV-1NL4-3 and its integrase mutant HIV-1NL4-3/D116N, HIV-
1AD8 and its integrase mutant HIV-1AD8/D116N were kindly provided by
Dr. Malcolm A. Martin. The HIV-1 envelope mutant plasmid pNL4-
3(KFS) was kindly provided by Dr. Eric Freed. The integrase mutant
plasmid pNL4-3(KFS)(D116N) was constructed by introducing a point
mutation (Asp 116 to Asn) into the integrase catalytic domain of pNL4-
3(KFS) as previously described (Iyer et al., 2009). The LTR-driven ex-
pression plasmids pLTR-GFP (pEV658) and pLTR-Tat-IRES-GFP
(pEV731) were kindly provided by Dr. Eric Verdin. pCMVΔR8.2,
pCMVΔR8.2(D116N), and pHCMV-G expressing vesicular stomatitis
virus (VSV) glycoprotein have been described previously (Wang et al.,
2010). pTRE-Tat86 and pTet-On were kindly provided by Dr. Ashok
Chauhan. pLTR-Luc was constructed from pNL-Luc-RRE-SA and pNL-
RRE-SA (Wu et al., 2007b) by inserting the luciferase gene (firefly)
within the XhoI cloning site of pNL-RRE-SA. pLTR-Tat-IRES-Luc was
generated from pLTR-TAT-IRES-GFP (pEV731) and pLTR-Luc. A PCR
product was generated from using pLTR-TAT-IRES-GFP (pEV731) as the
template. The PCR product contains the tat gene, IRES, and two ex-
ternal EcoRI sites. The PCR product and pLTR-Luc were both digested
with EcoRI and then ligated to generate plasmid pLTR-Tat-IRES-Luc.
2.3. Viruses, viral vectors, and viral infection
HIV-1NL4-3, HIV-1NL4-3/D116N, HIV-1AD8, and HIV-1AD8/D116N were
generated by transfection of plasmid DNAs into HEK293T cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as previously described
(Wu and Marsh, 2001). Supernatant was harvested at 48 h and filtered
through a 0.45 µm nitrocellulose membrane. Virus titer (TCID50) was
measured by infection of Rev-dependent GFP and GFP/Luc (green
fluorescent protein/Luciferase) duo reporter cell lines, Rev-CEM-GFP
and Rev-CEM-GFP-Luc (Wu et al., 2007a, 2007b) (Virongy, Manassas,
VA). NL4-3(KFS) and NL(KFS)(D116N) were produced by cotransfec-
tion of HEK293T cells with pHCMV-G and either pNL4-3(KFS) or pNL4-
3(KFS)(D116N) in a 1:1 ratio. vLTR-Tat-IRES-GFP and vLTR-Tat-IRES-
GFP(D116N) were produced by cotransfection of HEK293T cells with
pLTR-Tat-IRES-GFP, pHCMV-G, and either pCMVΔR8.2 or
pCMVΔR8.2(D116N) in a ratio of 4:1:3 respectively. vLTR-GFP and
vLTR-GFP(D116N) were produced by cotransfection of HEK293T cells
with pLTR-GFP, pHCMV-G, and either pCMVΔR8.2 or
pCMVΔR8.2(D116N) in a ratio of 4:1:3, respectively. vNL-Luc and virus
vNL-Luc(D116N) were constructed by co-transfection of HEK293T cells
with pLTR-Luc, pHCMV-G, and either pCMVΔR8.2 or
pCMVΔR8.2(D116N) in a 4:1:3 ratio, respectively. vLTR-Tat-IRES-Luc
and vLTR-Tat-IRES-Luc(D116N) were generated from co-transfection of
HEK293T cells with pLTR-Tat-IRES-Luc, pHCMV-G, and either
pCMVΔR8.2 or pCMVΔR8.2(D116N) in a 4:1:3 ratio, respectively. Viral
supernatant was harvested at 48 h postcotransfection, filtered through a
0.45-μm filter, and stored at−80 oC. Levels of p24 in viral supernatant
were measured using a Perkin Elmer Alliance p24 antigen enzyme-
linked immunosorbent assay kit (Perkin Elmer, Waltham, MA) or an in-
house p24 antigen ELISA kit. Viral infection of T cells and macrophages
were carried out as previously described (Kelly et al., 2008; Yoder et al.,
2008). HIV infection was also carried through spinoculation (Guo et al.,
2011), in which viral particles were added to the cells and subjected to
centrifugation for 2 h at 600×g (Guo et al., 2011). After centrifugation,
the medium was replaced with 1ml fresh RPMI 1640 medium supple-
mented with 10% heat-inactivated FBS and incubated at 37 oC for an-
other 48 h.
2.4. Cells and cell culture
Rev-dependent cell line Rev-CEM-GFP (Wu et al., 2007a, 2007b),
CEM-SS cells (Virongy, Manassas, VA), and U937 cells (from NIH AIDS
Reference and Reagent Program) were cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum (FBS)
(Invitrogen, Carlsbad, CA), penicillin (50 U/ml), and streptomycin
(50mg/ml). The integrase inhibitor, 118-D-24, was from NIH AIDS
Reference and Reagent Program (Svarovskaia et al., 2004). For infec-
tion, 2× 105 cells were incubated with 100–500 ng (p24) of virus for
2 h at 37 oC. Cells were washed, and then resuspended in fresh culture
medium. 1G5 cells (from NIH AIDS Reference and Reagent Program)
were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated. For infection, 5× 105 cells were either pre-treated with
etravirine (NIH AIDS Reference and Reagent Program) or not treated
for 1 h at 37 oC. The pre-treated cells were cultured in medium with the
continuous presence of the drug. Cells were infected with 300–500 ng
(p24) of virus for 4 h at 37 °C, washed, resuspended in fresh culture
medium, and then cultured for another 48 h. HeLa Tet-On Advanced
cells (Clontech Laboratories, Inc., Mountain View, CA) were cultured in
DMEM medium supplemented with 10% Tet System approved FBS
(Clontech Laboratories, Inc., Mountain View, CA) with G418 (100 µg/
ml). Macrophages were differentiated from human monocytes in the
peripheral blood mononuclear cells (PBMC). Briefly, 2.5× 106 PBMCs
were plated into each well of a 6-well plate in serum-free RPMI medium
for 1 h. Adherent cells were cultured in RPMI plus 10% heat-inactivated
FBS and 10 ng/ml macrophage colony stimulating factor (M-CSF) (R&D
System, Minneapolis, MN) for 2 weeks with medium change every 2
days. For infection, equal p24 input virus was added to the cells and
incubated at 37 °C for 4 h. Cells were washed twice and cultured in
RPMI 1640 supplemented with 10% heat-inactivated FBS, penicillin (50
U/ml), and streptomycin (50 µg/ml). Primary human microglia cells
were provided by Dr. Nazira El-Hage. Cells were cultured in DMEM
medium supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (Invitrogen, Carlsbad, CA), penicillin (50 U/ml), and strepto-
mycin (50mg/ml).
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2.5. Flow cytometry and cell sorting
For flow cytometry, 2× 105 CEM-SS cells were infected with equal
p24 input virus (5 ng) and incubated for 4 h at 37 °C. The cells were
washed once and resuspended in 1ml fresh RPMI 1640 supplemented
with 10% heat-inactivated FBS. GFP expression was measured at 48 h
post infection. Data analysis was performed using CellQuest (BD
Biosciences, San Jose, CA) and FlowJo (Tree Star, San Carlos, CA).
2.6. HDAC inhibitor stimulation
Apicidin (Sigma-Aldrich, St. Louis, MD), Sodium butyrate (Merck,
Darmstadt, Germany), and Valproic acid (Merck, Darmstadt, Germany)
were used to induce gene expression from the LTR of luciferase reporter
viruses. HDACis (histone deacetylase inhibitors) were dissolved at dif-
ferent concentrations in RPMI 1640 medium. Cells were infected with
equal amount of viral particles, cultured for various periods, stimulated
with HDACis for 24 h, harvested, and then analyzed for the luciferase
activity, using the amount of viral DNA in the lysates for normalization.
Viral DNA was quantified by quantitative real-time PCR as described
previously (Yoder et al., 2008). For luciferase assay, cells were rinsed
twice with cold 1× PBS. After the second rinse, cells were lysed in
500 µl of 1× reporter lysis buffer (Promega, Madison, Wisconsin) or
1× cell culture lysis reagent (Promega, Madison, Wisconsin). Firefly
luciferase activity was measured using the Promega Glomax Multi De-
tection system.
2.7. Doxycycline induction
HeLa Tet-On cells were transfected with 2 μg of either pTRE-Tat86
or pcDNA3.1+. After 5–6 h, the medium was replaced with fresh
DMEM supplemented with 10% Tet-On approved FBS, penicillin (50 U/
ml), and streptomycin (50mg/ml). After 24 h, cells were infected with
45 ng (p24) of reporter virus vLTR-Luc or vLTR-Luc(D116N) for 2 h at
37 oC. Cells were washed with DMEM supplemented with 10% Tet-On
approved FBS and with or without the 1 μg/ml of doxycycline. Cells
were harvest after 24 h for analyzing luciferase activity.
2.8. Viral DNA and RNA quantification
Total cellular DNA and RNA were purified using SV total RNA iso-
lation kit as recommended by the manufacture (Promega, Madison,
WI). Purified RNA was further treated with DNase I (DNA-free kit,
Invitrogen, Carlsbad, CA) as recommended by the manufacture. HIV
DNA was quantified by real-time PCR as described previously (Yoder
et al., 2008). For RNA reverse transcription, M-MLV reverse tran-
scriptase (Invitrogen, Carlsbad, CA) was used. For each reaction, 2 µl of
random decamers (50 µM) and 10 µl of RNA (100−200 ng) template
were mixed, and incubated at 80 °C for 3min, and then cooled down to
4 °C for 5min. Reaction was carried out in 20 µl containing 2 µl of
10× complete PCR buffer, 4 µl of dNTPs (2.5 mM), 10 U of RNase in-
hibitor, 100 U M-MLV reverse transcriptase. For the real-time PCR
assay, Taqman Gene Expression Master Mix (Invitrogen, Carlsbad, CA)
was used. The reaction mixture consisted of 25 µl of 2×Gene Expres-
sion Master Mix, 5 µl of 10× (2 µM) probe, 5 µl of 10× (3 µM) forward
primers, 5 µl 10× reverse primers, and 10 µl of DNA. For quantification
of the nef transcripts, the follow probe and primers were used: FAM-
Nef/Rev, 5’(56-FAM) CGGAGACAGCGACGAAGAGCTCATC (3 BHQ-1)
3’; 5’ Nef, 5’GGCGGCGACTGGAAGAA3’; 3’Rev, 5’AGGTGGGTTGCTTT
GATAGAGAAG3’. Quantitative real-time PCR analysis was carried out
using Bio-Rad iQ5 real-time PCR detection system.
2.9. ChIP assay
CHIP was carried as described previously (Tyagi and Karn, 2007).
Briefly, 30–100millions of human monocytic cell line, U937, were
infected with vLTR-Luc or vLTR-Luc(D116N), and cells were harvested
at 4, 12, and 24 h. Antibodies were purchased from Santa Cruz, in-
cluding anti-RNAP II (N-20), HDAC-1 (H-51), and p65 (C-20). Anti-
acetylated histone-3 and −4 antibodies were obtained from Upstate
Biotech (Fisher Scientific). Each sample (5%) was analyzed by quanti-
tative real-time PCR to access the amount of sample im-
munoprecipitated by individual antibody. A non-antibody control value
was subtracted from each sample value to remove the background
counts.
3. Results
3.1. Preintegration transcription occurs at a homogenously low level
Preintegration transcription from uDNA has been shown to produce
a viral early protein Nef (Wu and Marsh, 2001, 2003). The two other
viral early proteins, Tat and Rev, are presumably also produced. Both
proteins are difficult to detect even in wild-type (WT) HIV-infected cells
by Western blot. To measure the activity of Tat and Rev from uDNA, we
used an HIV Tat and Rev-dependent GFP (green fluorescent protein)
indicator CD4 T cell line, Rev-CEM-GFP, which expressed GFP upon
HIV infection and Tat/Rev expression (Wu et al., 2007a, 2007b). Rev-
CEM-GFP was infected with WT HIV-1NL4-3 or its integrase mutant, HIV-
1NL4-3(D116N). As shown in Fig. 1A, both WT and D116N infection of
Rev-CEM-GFP resulted in GFP positive cells, suggestive of the expres-
sion of Tat and Rev. Further quantification revealed that the GFP cell
percentage in D116N infection (4.1%) was comparable to that of WT
infection (5.5%) (using an equal p24 level for infection), indicating a
similar number of transcribing DNA templates with or without in-
tegration (Iyer et al., 2009). However, when the GFP intensity was
quantified, in D116N-infected cells, GFP expression was universally at a
low level (mean intensity = 38.0) (Fig. 1A, right panel). This was in
great contrast to the WT infection, which generated GFP-positive cells
of varied intensities across two orders of magnitude (mean intensity =
280.6). Similar results were also observed when an integrase inhibitor,
118-D-24, was used to block WT HIV integration (Fig. 1B). Given this
homogenously low GFP activity from uDNA in D116N infection, it is
uncertain whether Tat is indeed generated early and functionally in-
volved in stimulating uDNA transcription.
3.2. de novo Tat activity is generated from uDNA
Western blot detection of Tat protein is difficult even with WT in-
fection, but the demonstration of Tat activity is achievable. We used a
LTR-driving luciferase reporter cell line, 1G5 (Aguilar-Cordova et al.,
1994), to measure Tat stimulation of LTR from the integrase mutant,
HIV-1(D116N). We observed a great enhancement of the LTR-driving
luciferase expression following infection of 1G5 with D116N (Fig. 2A).
However, the intrinsic leakiness of the LTR promoter in indicator cells
such as 1G5 made the measurement of low-level HIV transcription
problematic, as stimuli such as cytokines, mitogens (Aguilar-Cordova
et al., 1994; Akan et al., 1997; Siekevitz et al., 1987; Sweet and Hume,
1995; Swingler et al., 1992, 1994), or the viral particle binding itself
(Merzouki et al., 1995) may also trigger Tat-independent reporter ex-
pression. Thus, we pre-treated cells with a reverse transcriptase in-
hibitor, etravirine, which largely diminished the enhancement of the
luciferase activity. This demonstrated that the D116N-stimulated luci-
ferase activity was indeed dependent on newly-synthesized viral DNA,
and likely newly-synthesized Tat from uDNA.
To further confirm the involvement of the uDNA-derived Tat (uTat)
in uDNA transcription, we assembled an unintegrating lentiviral vector,
pLTR-GFP-IRES-Tat(D116N), that expresses both Tat and GFP from the
LTR promoter (Fig. 2B). Infection of human T cells with vLTR-GFP-
IRES-Tat(D116N) resulted in the expression of low-level GFP, in com-
parison with a control integrating viral vector, vLTR-GFP-IRES-Tat.
Deletion of Tat from these vectors generated vLTR-GFP(D116N) and
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vLTR-GFP (Fig. 2B). When cells were similarly infected (using equal
p24 of the Tat+ and Tat- viruses), the deletion of Tat greatly diminished
the GFP expression in vLTR-GFP(D116N) infection (96% reduction)
(Fig. 2B). Similar deletion of Tat from the integrating vector, vLTR-GFP-
IRES-Tat, also diminished the GFP cell population, although to a less
extent (85%). This result confirmed that Tat is also required to stimu-
late the low level gene expression from uDNA. Intriguingly and con-
sistent with the result in Fig. 1, even Tat is required, without integra-
tion, Tat cannot stimulate LTR to the high levels of GFP expression seen
in the integrated vector, suggesting that the sites of LTR integration and
local cellular chromatin environment may have a profound impact on
the LTR responsiveness to Tat transactivation.
3.3. Different responsiveness of uDNA and provirus to Tat stimulation
To further quantitatively measure the differences between in-
tegrated versus uDNA templates, for their responsiveness to Tat, we
established a doxycycline-inducible Tat expression system, in which a
doxycycline-responsive transactivator (drTA)-expressing HeLa cell
(HeLa Tet-On, Clontech) was transfected with a doxycycline-inducible
Tat expression vector, pTRE-Tat86 (Fig. 3A). Following doxycycline
induction, activated drTA binds to TRE (Tetracycline Responsive Ele-
ment) on the promoter region of pTRE-Tat86, activating Tat expression.
HeLa Tet-On/pTRE-Tat86 or a control cell, HeLa Tet-On/pCDNA3.1,
were infected with a reporter virus, vLTR-Luc, or its unintegrating form,
vLTR-Luc(D116N). Both of them express luciferase as the sole protein
from the LTR-promoter. Following doxycycline induction of Tat, LTR-
driving luciferase activity was measured. As shown in Fig. 3B, for the
integrating virus, vLTR-Luc, Tat-induction stimulated a 8.2- to 12.5-fold
increase in the luciferase activity (at day 2 and 3), whereas for the non-
integrating virus, vLTR-Luc(D116N), similar Tat-induction also led to
an increase in the luciferase activity, but it is only 1.9–1.6-fold (Fig. 3C)
(23–13% of integrated). The enhancements were dependent on Tat, as
in the absence pTRETat86 doxycycline induction itself does not sti-
mulate the luciferase activity in infected cells (Fig. 3B and C). These
results confirmed that Tat is capable of stimulating uDNA transcription,
but the uDNA LTR is less responsive to Tat than integrated LTR.
3.4. Tat antagonizes minichromatin repression to promote persistent uDNA
transcription in primary macrophages
It has been shown that a large amount of uDNA accumulates in
brain tissues that are infected through migrating peripheral macro-
phages (Pang et al., 1990). In cell culture conditions, uDNA and its
transcripts can persist in macrophages for as long as 20–30 days (Kelly
et al., 2008). We confirmed these previous results by infecting blood
monocytes-derived macrophages (MDM) and primary human microglia
with an integrating or unintegrated virus, HIV-1(KFS) or HIV-1(KFS
(D116N), and observed the persistence of uDNA and its nef transcripts
(Fig. 4), consistent with previous results (Kelly et al., 2008). To further
determine whether uTat is required for the transcriptional persistence
of uDNA in macrophages, we generated a Tat-negative LTR-driving
luciferase reporter vector, pLTR-Luc. Integrated and unintegrated len-
tiviral particles, vLTR-Luc and vLTR-Luc(D116N) respectively, were
assembled and used to infect MDM (Fig. 5A). As shown in Fig. 5B, we
observed LTR-driving luciferase activity at day 5 post infection with
both vNL-Luc and vNL-Luc(D116N) (Fig. 5B, Control). However,
without Tat, the activity was largely diminished at day18 post infection
(Fig. 5C, Control). This diminished transcriptional activity is in great
contrast to the persistent transcription (20–30 days) seen in the Tat+
HIV(D116N) infection of macrophages (Kelly et al., 2008). The loss of
transcriptional activity did not result from possible losses of viral DNA
templates, as they were readily detectable in cells infected with vLTR-
Luc or vLTR-Luc(D116N) (data not shown). It is possible that repressive
histones may be assembled onto the LTR region that is gradually si-
lenced in the absence of Tat. Thus, we stimulated infected cells with 3
different histone deacetylase (HDAC) inhibitors, apicidin, sodium bu-
tyrate (NaBut), and valproic acid (VPA). As shown in Fig. 5B, at day 5
post infection, apicidin and NaBut are capable of stimulating gene ex-
pression from the both integrated and unintegrated LTR. However, VPA
had minimal effect, and was slight inhibitory for integrated proviral
DNA. Although VPA inhibits histone deacetylase, it can also induce cell
Fig. 1. Preintegration transcription occurring at a homogenously low level. (A) An HIV Rev-dependent reporter cell line, Rev-CEM-GFP, was infected with an equal p24 level of HIV-1NL4-3
(Wt) or an integrase mutant, D116N. The percentage of GFP-positive cells was measured at 48 h post infection with flow cytometry (density plot, left panel). The average mean intensity of
GFP in the GFP-positive cells is also shown (histoplot, right panel). (B) The integrase inhibitor, 118-D-24 (50 μM), was used to treat Rev-CEM-GFP cells for 4 h prior to HIV-1 infection.
Cells treated with 118-D-24 or untreated were then infected with an equal p24 level of the Wt virus for 2 h. Following infection, cells were cultured in the continuous presence of 118-D-
24. The percentage (%) and average GFP intensity (M) of GFP-positive cells were measured at 48 h with flow cytometry. All these experiments have been repeated 3 times.
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differentiation and selectively inhibits the transcription of certain genes
such as AKT1/AKT2, which are important for HIV infection (Chen et al.,
2006). For the unintegrated LTR, apicidin stimulated a 3.4-fold increase
in luciferase expression, while NaBut induced a 4.0-fold increase. For
the integrated LTR, we observed up to 2.7- and 2.0-fold enhancement
by these two drugs, respectively. At day 18, when similar HDACi sti-
mulation was performed, we observed a dramatic stimulation of the
LTR activity. For the uDNA LTR, we observed an approximately 100-
fold increase by apicidin and NaBut, whereas for the integrated LTR, we
observed an approximately 8000-fold enhancement by NaBut. This
dramatic enhancement was observed in the low transcription back-
ground in the absence of Tat, suggesting that repressive chromatin may
have been assembled.
Next, we tested whether Tat is indeed capable of antagonizing re-
pressive chromatin in MDM. Tat has been shown to directly bind to
components of the ATP-dependent chromatin remodeling complex SWI-
SNF (Agbottah et al., 2006; Mahmoudi et al., 2006; Treand et al., 2006)
and recruits the complex to the HIV promoter (Agbottah et al., 2006;
Mahmoudi et al., 2006; Treand et al., 2006). In addition, Tat can bind
to HAT (histone acetyltransferase) such as p300/CBP, pCAF, and
hGCN5 (Benkirane et al., 1998; Col et al., 2001; Hottiger and Nabel,
1998; Kamine et al., 1996; Marzio et al., 1998), which may mediate
acetylation of nucleosomes to enhance Tat-mediated transactivation
(Gatignol, 2007; Kiernan et al., 1999). To determine impacts of Tat on
LTR responsiveness to histone modulation, we constructed a lentiviral
vector, pLTR-Tat-IRES-Luc, in which both Tat and luciferase are co-
expressed from the LTR. For comparison, we also used the Tat-negative
vector, pLTR-Luc, as described above. Intergrated and unintegrated
viral particles were assembled, and then used to infect MDM (Fig. 6A).
At 5 days post infection, cells were treated with NaBut to stimulate the
LTR transcription. As shown in Fig. 6B and C, when Tat was expressed
from integrated or uDNA templates, it stimulated high luciferase ac-
tivity. However, NaBut did not stimulate the LTR further when Tat is
present. In contrast, when Tat was deleted, upon the low transcriptional
background, NaBut stimulated an approximately 5-fold enhancement
from the integrated and unintegrated LTR (Fig. 6B and C, right panel).
These results suggest that Tat itself may function to antagonize the
chromatin repression to maintain persistent transcription in primary
macrophages.
To further confirm that minichromatin is indeed assembled onto
uDNA, we infected a monocyte cell, U937, with integrating vLTR-Luc or
unintegrating vLTR-LTR (D116N) and performed the chromatin
Fig. 2. de novo Tat activity from uDNA and its transactivation of preintegration transcription. (A) de novo Tat activity from uDNA. An HIV Tat-dependent indicator cell line, 1G5 cells were
infected with the integrate mutant, HIV-1(D116N). For comparison, cells were also pre-treated with the reverse transcriptase inhibitor etravirine. Equal number of cells were lysed and
luciferase activity measured at 48 h post infection. Uninfected 1G5 cells were used as a control. The experiment has been repeated 4 times. (B) Tat-mediated transactivation of
preintegration transcription from uDNA. Lentiviral particles with and without the Tat gene (pLTR-GFP-IRES-Tat and pLTR-GFP), and their integrase mutants, pLTR-GFP-IRES-Tat(D116N)
and pLTR-GFP)(D116N), were assembled and used to transduce CEM-SS cells. Equal p24 levels of the Tat+ and Tat- viral particles were used. GFP expressions were measured by flow
cytometry at 72 h post infection. The experiments have been repeated 4 times.
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immunoprecipitation (ChIP) assay at 4, 12, and 24 h post infection. HIV
LTR contains two well-ordered nucleosomes, Nucleosome 0 (Nuc-0) and
nucleosome 1 (Nuc-1). Nuc-0 is positioned immediately upstream of the
enhancer (−415 to −255), while Nuc-1 is very close to the viral RNA
start site (+10 to +155). We examined chromatin modifications and
the recruitment of responsible epigenetic enzymes at the HIV LTR. As
shown in Fig. 7, we observed immediate enrichment of acetylated
histones and enhanced recruitment of RNAP II even at 4 h post infec-
tion, showing ongoing gene expression from the LTR promoter. We also
noted the higher binding of NF-kB (p65), specifically at its cognate
binding sites, which validates specific NF-kB recruitment. In addition,
we observed acetylated histone H3 and repressive HDAC-1 on Nuc-1,
suggesting that histone deacetylation may also occur in the absence of
Tat. Overall, for both integrated and unintegrated HIV genomes, we
found chromatin assembly, demonstrating that immediately after entry
into cells, HIV DNA interacts with histones and assemble itself into
chromatin structures. The levels of recruitment of different factors were
relatively less pronounced at unintegrated DNA, suggesting that
Fig. 3. Different responsiveness of HIV uDNA and provirus to
Tat stimulation. (A) Schematic representation of the dox-
ycycline-inducible Tat expression system. HeLa cells (HeLa
Tet-On) were stably transfected with a plasmid vector ex-
pressing the doxycycline-responsive transcriptional activator,
and then transfected with a doxycycline-inducible Tat ex-
pression vector, pTRE-Tat86, or a control empty vector,
pCDNA3.1. Cells were subsequently infected with a lentiviral
particle, vLTR-Luc or its integrase mutant, vLTR-Luc(D116N)
(equal p24 for pTRE-Tat86 and pCDNA3.1 transfected cells).
Cells were infected with our without Tat-induction by dox-
ycycline. (B) Cells were infected with vLTR-Luc, and luci-
ferase activity was measured at day 1–3 post infection. (C)
Cells were infected with vLTR-Luc(D116N), and luciferase
activity was measured at day 1–3 post infection. The mean
luciferase activity was from experimental triplicates.
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genomic integration promotes the chromatin organization of proviral
DNA, and HIV uDNA may have a different chromatin structure.
4. Discussion
In this article, we provided evidence that de novo Tat activity is
generated from HIV uDNA, and this uTat can stimulate HIV uDNA LTR.
Functionally, this uTat is important in antagonizing repressive mini-
chromatin that is assembled onto uDNA, permitting persistent tran-
scription to occur in immune cells such as macrophages (Kelly et al.,
2008). Given the accumulation of a large amount of uDNA in lymphoid
tissues and in the brain, this uTat-mediated low level transcription may
contribute to the persistence of viral reservoirs in tissues.
Levy and co-authors has suggested that HIV uDNA transcription is
important for the maintenance of viral genetic diversity (Gelderblom
et al., 2008; Wodarz et al., 2014; Wu, 2008), as only a small percentage
of viral genomes can integrate. Most viral genomes exist as uDNA that
can transcribe genomic RNAs (Kelly et al., 2008; Wu and Marsh, 2001,
2003). These RNA genomes are also rescuable for co-packaging, and
capable of supporting continuous viral replication (Gelderblom et al.,
2008). In the absence of immune stimulation, uDNA transcription has
also been shown to produce a viral early protein Nef (Kelly et al., 2008;
Wu and Marsh, 2001, 2003), which can modulate resting T cell activity
to favor viral replication (Wu and Marsh, 2001). Remarkably, recent
Fig. 4. Persistent transcription from HIV uDNA in primary
macrophages and microglia. (A) Monocyte-derived macro-
phages were infected with an equal p24 level of HIV-NL(KFS)
or its non-integrating mutant HIV-vNL(KFS)(D116N) for 5 and
19 days. Cells were lysed and total cellular DNA and RNA
were extracted and used for the quantification of viral DNA
and Nef mRNA by real-time PCR and real-time reverse tran-
scriptase PCR. (B) The relative ratio of Nef mRNA and HIV
DNA was plotted. (C) Primary human microglia were infected
with the non-integrating HIV-NL(KFS)(D116N) for 3 days.
Cells were lysed and total cellular DNA and RNA were ex-
tracted and used for the quantification of viral DNA and Nef
mRNA by real-time PCR and real-time reverse transcriptase
PCR.
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results have also demonstrated that in resting CD4 T cells and primary
macrophages, this low-level transcriptional activity can be greatly up-
regulated by cytokines, T cell activation, or latency reversing agents,
leading to low-level production of replication-competent viruses (Chan
et al., 2016; Kantor et al., 2009; Trinite et al., 2013). These studies
support the possibility that viral uDNA genomes can serve as alternative
Fig. 5. Responses of HIV uDNA to HDAC inhibitor stimulation. (A)
Schematics of lentiviral particle assembly. Integrating lentiviral particle
vLTR-Luc and its integrase mutant vLTR-Luc(D116N) were assembled by
cotransfection with pCMVΔR8.2 or pCMVΔR8.2(D116N), and a VSV-G
expression vector, pHCMV-G. Particles were harvested and used to infect
monocyte-derived macrophages (MDM) as shown in (B) and (C). (B) At 5
days post infection with vLTR-Luc or vLTR-Luc(D116N), cells were sti-
mulated with apicidin, sodium butyrate (NaBut), and valproic acid
(VPA), and harvested for luciferase assay. Control cells were infected but
not treated with HDAC inhibitors. HIV viral genomic DNA in cell lysates
was quantified for normalization. (C) At 18 days post infection with
vLTR-Luc or vLTR-Luc(D116N), cells were identically stimulated and
analyzed. The mean luciferase activity was from experimental triplicates.
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reservoirs different from integrated proviral reservoirs in blood T cells
and tissues (Petitjean et al., 2007), where a large amount of uDNA
accumulates to form the predominant species of viral DNA (Chun et al.,
1997; Pang et al., 1990; Pauza et al., 1990; Shaw et al., 1984; Teo et al.,
1997).
In a previous animal monotherapy trial of the integrase inhibitor,
Fig. 6. Effects of Tat on HIV uDNA responses to HDACi stimulation. (A)
Schematics of lentiviral particle assembly. Integrating lentiviral particles,
vLTR-Luc or vLTR-Tat-IRES-Luc, and their integrase mutants, vLTR-Luc
(D116N) or Tat-IRES-Luc(D116N), were assembled by cotransfection with
pCMVΔR8.2 or pCMVΔR8.2(D116N), and a VSV-G expression vector,
pHCMV-G. Particles were harvested and used to infect monocyte-derived
macrophages (MDM) as shown in (B) and (C). (B and C) MDMs were in-
fected with an equal p24 level of vLTR-Tat-IRES-Luc or vLTR-Luc, either
integrating (B) or non-integrating (C). At 5 days post infection, cells were
stimulated with sodium butyrate (NaBut), harvested, and analyzed for lu-
ciferase activity. Control cells were infected but not treated with HDAC
inhibitors. HIV viral genomic DNA in cell lysates was quantified for nor-
malization. The mean luciferase activity was from experimental triplicates.
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Fig. 7. Assembly of minichromatin onto HIV uDNA in macrophages. U937 cells, a monocytic cell line, were infected with the integration and non-integrating reporter particle vNL-Luc
(A) or vNL-Luc(D116N) (B). Cells were cross-linked at 4, 12, and 24 h post infection, and ChIP assay was performed. On every run, 5% of each sample was analyzed by quantitative real-
time PCR to determine the amount of sample immunoprecipitated by individual antibodies. Specific primer sets were used to amplify different regions of the LTR. The reading obtained
with preimmune sera was subtracted as background counts.
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L870812, the drug effectively inhibited acute SIV replication in rhesus
macaques following early treatment (day 10 after infection) (Hazuda
et al., 2004). However, the inhibitor was not effective in controlling
viremia when used at a later time (day 87 post infection); the drug
failed to persistently suppress viral load in 5 of the 6 animals (Hazuda
et al., 2004). This is in great contrast to reverse transcriptase inhibitors
in viremia control. Importantly, the recovered viruses were found to
remain wild type in the integrase sequence (Hazuda et al., 2004). Given
this intrinsic viral resistance to L-870812, it could suggest that the ac-
cumulation of HIV uDNA following L870812 treatment may lead to low
level viral replication from the uDNA, especially in later disease stages
when cytokines and other immune factors are dysregulated (Chan et al.,
2016; Kantor et al., 2009; Trinite et al., 2013). In cell culture condi-
tions, uDNA accumulation does not lead to viral replication in resting
CD4 T cells and macrophages (Kelly et al., 2008; Wu and Marsh, 2001).
However, if resting T cells or macrophage are cultured in cytokines or
histone deacetylase inhibitors, and then stimulated, low level viral re-
plication can occur from uDNA (Chan et al., 2016; Kantor et al., 2009;
Trinite et al., 2013).
Consistent with the animal trial (Hazuda et al., 2004), in recent
human HAART intensification studies, although the integrase inhibitor
raltegravir (RAL) increased the amounts of unintegrated 2-LTR circles,
it did not reduce the residual viremia, nor the total amount of viral DNA
(Gandhi et al., 2012, 2010; Shi et al., 2014). Compared with RAL, the
second generation integrase inhibitor dolutegravir (DTG) has been
found to bring faster plasma viral load decay when used in combination
with reverse transcriptase (RT) inhibitors (Clotet et al., 2014; Raffi
et al., 2013; Walmsley et al., 2013). It is possible that the integrase
inhibitor may block integration of residue uDNA. Nevertheless, mul-
tiple clinical studies have found that the integrase inhibitor resistant
viruses from at least half of the patients do not have mutations in the
integrase region (Fourati et al., 2015; Malet et al., 2017; White et al.,
2015). Consistently, a recent study has isolated a replication competent
virus that is highly resistant to all clinical integrase inhibitors (Malet
et al., 2017); intriguingly, sequencing of the viral genome showed no
mutations in the integrase gene, and the integrase enzymatic activity
remains sensitive to the integrase inhibitors. These studies support the
hypothesis that uDNA could contribute to viral persistence and residual
viremia that may not be reduced by blocking integration. A recent
mathematical modeling has suggested that uDNA could contribute to
20% of total viremia in HIV infection (Lau et al., 2015).
Our results suggest that HIV Tat plays an important role in the
persistence of viral transcription from uDNA. Tat stimulates uDNA
transcription likely through various mechanisms; Tat promotes the
processivity of polymerase II through P-TEFb, and antagonizes re-
pressive chromatin through binding to chromatin remodeling com-
plexes and HAT (Benkirane et al., 1998; Col et al., 2001; Hottiger and
Nabel, 1998; Kamine et al., 1996; Marzio et al., 1998). Intriguingly,
there is a clear distinction in response to Tat stimulation between in-
tegrated provirus and uDNA; although Tat is required for uDNA tran-
scription, uDNA is less responsive to Tat than provirus (Fig. 3 and
Fig. 5). The mechanism regulating such differences is not currently
understood. It is possible that the chromatin structure assembled onto
uDNA may be different from that assembled onto integrated provirus.
HIV can integrate into both heterochromatin and euchromatin, leading
to different levels of basal transcription. The LTR responses to Tat
would be greater in the heterochromatin than in the euchromatin. Such
structural diversity may not be present in uDNA.
In conclusion, our study demonstrated a critical role of Tat in
mediating persistent transcription from uDNA, which could serve as a
residual viral reservoir. Targeting Tat is critical, and may offer a way to
silence uDNA and reduce its persistence in immune cells.
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